Noticias de SNY_US

Noticias del mercado

Últimas noticias sobre SNY_US — 151 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: SNY_US ✕ 151 resultados
24/04/2026 SNY_US — Investing.com
Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments By GuruFocus
24/04/2026 SNY_US — Trade Brains
Pharma Stock Jumps 10% After Company to Acquire Sanofi Portfolio for ₹1,740 Cr
24/04/2026 SNY_US — CNBC TV18
Gujarat Themis shares jump 10% on €158 million Sanofi anti-TB portfolio deal
24/04/2026 SNY_US — NDTV Profit
Gujarat Themis Biosyn To Acquire Sanofi Portfolio For Rs 1,700 Crore
24/04/2026 SNY_US — FirstWord Pharma
Friday Five – Updates from AACR, ASCO and AAN, Sanofi's second life for Dupixent, Regeneron's free gene therapy, and more…
23/04/2026 SNY_US — TradingView
Key facts: Sanofi Q1 strong; Dupixent €4.17B; U.S. pricing may lift EU; Garijo CEO
23/04/2026 SNY_US — TipRanks
Gujarat Themis Biosyn to Buy Sanofi Anti-Infective Brands in €158 Million Deal
23/04/2026 SNY_US — TipRanks
Gujarat Themis Biosyn Unveils Investor Presentation on Sanofi Anti-TB Asset Purchase
23/04/2026 SNY_US — TipRanks
Gujarat Themis Biosyn to Buy Sanofi’s Global Anti-TB and Anti-Infective Brands
23/04/2026 SNY_US — Investor's Business Daily
Sanofi Jumps On Dupixent-Led Beat With New CEO Coming
23/04/2026 SNY_US — Il Sole 24 ORE
Sanofi, revenues and profits up in Q1
23/04/2026 SNY_US — TipRanks
Sanofi Advances Amlitelimab Program With Key Drug-Interaction Study Completion
23/04/2026 SNY_US — MarketScreener
Sanofi: Quarterly beat is fine, but longer-term growth prospects remain questionable
23/04/2026 SNY_US — Yahoo Finance
BNP Paribas Downgrades Sanofi (SNY) with ‘Unlikely Near-Term Rerating’
23/04/2026 SNY_US — Yahoo Finance
How The Sanofi (ENXTPA:SAN) Narrative Is Shifting After Valuation Reset And Pipeline Updates
23/04/2026 SNY_US — BioPharma Dive
Sanofi posts upbeat sales as R&D pressure builds
23/04/2026 SNY_US — WebWire
Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
23/04/2026 SNY_US — Benzinga
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
23/04/2026 SNY_US — MarketScreener
SANOFI : Barclays reiterates its Neutral rating
23/04/2026 SNY_US — BioSpace
Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

Página 1 de 8

keyboard_arrow_up